Financhill
Back

Oculis Holding AG Quote, Financials, Valuation and Earnings

Oculis Holding AG Price Quote

$12.00
+0.06 (+0.5%)
(Updated: September 16, 2024 at 2:55 PM ET)

Oculis Holding AG Key Stats

Sell
23
Oculis Holding AG (OCS) is a Sell

Day range:
$11.88 - $12.05
52-week range:
$9.05 - $14.47
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.97%

Volume:
45.5K
Avg. volume:
26.5K
1-year change:
-3.08%
Market cap:
$498.4M
Revenue:
$0
EPS:
$-2

How Much Does Oculis Holding AG Make?

Data Unavailable

Is Oculis Holding AG Growing As A Company?

Data Unavailable

Oculis Holding AG Stock Price Performance

  • Did Oculis Holding AG Stock Go Up Last Month?
    Oculis Holding AG share price went up by 4.28% last month
  • Did OCS's Share Price Rise Over The Last Year?
    OCS share price fell by -3.08% over the past 1 year

What Is Oculis Holding AG 52-Week High & Low?

Oculis Holding AG Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Oculis Holding AG?

  • How Much Debt Does Oculis Holding AG Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Oculis Holding AG Have?
    Cash and short term investments quarterly total is $131.2M
  • What Is Oculis Holding AG’s Book Value Per Share?
    Book value per share is 3.01

Is Oculis Holding AG Cash Flow Positive?

  • What Is OCS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$57.4M
  • What Is Oculis Holding AG’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $58.7M
  • What Is Oculis Holding AG’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.9M

Oculis Holding AG Return On Invested Capital

Data Unavailable

Oculis Holding AG Earnings Date & Stock Price

Oculis Holding AG Competitors

  • Who Are Oculis Holding AG's Competitors?
    Below is a list of companies who compete with Oculis Holding AG or are related in some way:
    • AC Immune SA (ACIU)
    • Addex Therapeutics Ltd (ADXN)
    • CRISPR Therapeutics AG (CRSP)
    • Molecular Partners AG (MOLN)
    • NLS Pharmaceutics Ltd (NLSP)

Oculis Holding AG Dividend Yield

Oculis Holding AG Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -44.52%
Revenue: 0% 3.72%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 28.81
Upside from Last Price: 141.32%

Major Shareholders

  • How many OCS shares are owned by institutional investors?
    3.5M OCS shares are owned by institutional investors
  • How many OCS shares are owned by insiders?
    0 OCS shares are owned by insiders